Arthur P. Bollon
Vorstandsvorsitzender bei Vitruvian BioMedical, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Kai P. Larson | M | 60 |
SignPath Pharma, Inc.
 SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 9 Jahre |
| Jack Levine | M | 73 |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 14 Jahre |
| LaCarl T. Satcher | M | - |
Vitruvian BioMedical, Inc.
 Vitruvian BioMedical, Inc. Miscellaneous Commercial ServicesCommercial Services Vitruvian BioMedical, Inc. engages in the biotechnology industry. It develops and commercializes diagnostics and therapeutics for individualized and balanced healthcare with an initial focus on Alzheimer's Disease. The company was founded by Arthur P. Bollon, T. LaCarl Satcher and Rhonda R. Porterfield and is headquartered in Addison, TX. | - |
| Rhonda R. Porterfield | M | - |
Vitruvian BioMedical, Inc.
Vitruvian BioMedical, Inc. Miscellaneous Commercial ServicesCommercial Services Vitruvian BioMedical, Inc. engages in the biotechnology industry. It develops and commercializes diagnostics and therapeutics for individualized and balanced healthcare with an initial focus on Alzheimer's Disease. The company was founded by Arthur P. Bollon, T. LaCarl Satcher and Rhonda R. Porterfield and is headquartered in Addison, TX. | - |
| Robert Seguso | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 7 Jahre |
| Peter Sordillo | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 7 Jahre |
| Stephen Spencer | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 7 Jahre |
| Gregory M. Heard | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 5 Jahre |
| Jeffrey S. Starman | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 3 Jahre |
| Bradley J. Hayosh | M | - |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robert E. Dragoo | M | 84 |
Hemobiotech, Inc.
 Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | - |
| Lawrence Helson | M | 93 |
SignPath Pharma, Inc.
SignPath Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SignPath Pharma, Inc. operates as a development stage biotechnology company. It engages in the research and development of curcumin formulations for the treatment of cancer, neurologic disorders and mitigates drug-induced cardiac arrhythmia. The company was founded by Bruce Meyers in May 15, 2006 and is headquartered in Sandy, UT. | - |
| Robert A. Baron | M | 84 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | - |
| Robert W. Comer | M | 91 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | - |
| Mark Rosenblum | M | 70 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | 4 Jahre |
| Bernhard Mittemeyer | M | 93 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | - |
| Walter Haeussler | M | 87 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | 4 Jahre |
| Mario Feola | M | 97 |
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 18 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Arthur P. Bollon
- Persönliches Netzwerk
